Cognition Therapeutics Files 8-K
Ticker: CGTX · Form: 8-K · Filed: Mar 11, 2024 · CIK: 1455365
| Field | Detail |
|---|---|
| Company | Cognition Therapeutics INC (CGTX) |
| Form Type | 8-K |
| Filed Date | Mar 11, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $25.6 million, $29.9 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, financial-reporting
TL;DR
Cognition Therapeutics filed an 8-K on March 11, 2024, for financial reporting.
AI Summary
Cognition Therapeutics, Inc. filed an 8-K on March 11, 2024, reporting on its results of operations and financial condition. The filing does not contain specific financial figures or operational details in the provided text, but indicates a standard reporting event for the company.
Why It Matters
This filing signifies a routine update on the company's financial status and operational results, which is important for investors to monitor the company's performance.
Risk Assessment
Risk Level: low — This is a standard 8-K filing for reporting financial results and does not appear to contain any new or unusual information that would immediately impact risk.
Key Players & Entities
- Cognition Therapeutics, Inc. (company) — Registrant
- March 11, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-40886 (company_id) — Commission File Number
- 13-4365359 (tax_id) — I.R.S. Employer Identification No.
- 2500 Westchester Avenue Purchase, NY 10577 (address) — Address of principal executive offices
- ( 412 ) 481-2210 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Cognition Therapeutics, Inc.'s results of operations and financial condition as of March 11, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on March 11, 2024.
In which state is Cognition Therapeutics, Inc. incorporated?
Cognition Therapeutics, Inc. is incorporated in Delaware.
What is the Commission File Number for Cognition Therapeutics, Inc.?
The Commission File Number for Cognition Therapeutics, Inc. is 001-40886.
What is the address of Cognition Therapeutics, Inc.'s principal executive offices?
The address of Cognition Therapeutics, Inc.'s principal executive offices is 2500 Westchester Avenue Purchase, NY 10577.
Filing Stats: 793 words · 3 min read · ~3 pages · Grade level 15.2 · Accepted 2024-03-11 16:11:59
Key Financial Figures
- $0.001 — h Registered Common Stock, par value $0.001 per share CGTX The Nasdaq Stock Mar
- $25.6 million — 1, 2023 is expected to be approximately $25.6 million. As of December 31, 2023, the Company
- $29.9 million — 31, 2023, the Company had approximately $29.9 million in cash and cash equivalents. The abo
Filing Documents
- tm248362d1_8k.htm (8-K) — 27KB
- 0001104659-24-032979.txt ( ) — 196KB
- cgtx-20240311.xsd (EX-101.SCH) — 3KB
- cgtx-20240311_lab.xml (EX-101.LAB) — 33KB
- cgtx-20240311_pre.xml (EX-101.PRE) — 22KB
- tm248362d1_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition. Preliminary unaudited consolidated operating results for the year ended December 31, 2023 and certain preliminary financial condition information as of December 31, 2023 are as follows: Net loss for the year ended December 31, 2023 is expected to be approximately $25.6 million. As of December 31, 2023, the Company had approximately $29.9 million in cash and cash equivalents. The above information is preliminary unaudited consolidated financial information for the year ended December 31, 2023 and is subject to completion. The unaudited, estimated results for the year ended December 31, 2023 are preliminary and were prepared by the Company's management, based upon the Company's estimates, a number of assumptions and currently available information, and are subject to revision based upon, among other things, year-end closing procedures and/or adjustments, the completion of the Company's audited financial statements and other operational procedures. This preliminary financial information is the responsibility of management and has been prepared in good faith on a consistent basis with prior periods. However, the Company has not completed its audited financial statements for the year ended December 31, 2023, and its actual results could be materially different from this preliminary financial information, which preliminary information should not be regarded as a representation by the Company or its management as to its actual results for the year ended December 31, 2023. In addition, the Company's independent registered public accounting firm has not completed its audit procedures with respect to this preliminary financial information and does not express an opinion or any other form of assurance with respect to this preliminary financial information. During the course of the preparation of the Company's financial statements and related notes as of and for the year ended December 31, 2023, the Company may id
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. COGNITION THERAPEUTICS, INC. By: /s/ Lisa Ricciardi Name: Lisa Ricciardi Title: President and Chief Executive Officer Date: March 11, 2024